Medical therapies and mechanical interventions for the treatment of myocardial infarction (MI) and ischemic heart failure have seen great progress. However, current therapies only slow the progression to heart failure, but do not stimulate regeneration to recover the loss of functional myocytes. Stem cell-based therapy is a novel modality that can potentially be used for the treatment of ischemic cardiac injury and heart failure wherein cardiac tissue is regenerated thereby improving cardiac function and reducing the morbidity and mortality of patients. Many preclinical and clinical trials have employed various types of stem cells including bone marrow-derived mononuclear cells, skeletal myoblasts, resident cardiac stem cells, mesenchymal stem cells, and endothelial progenitor cells, and these studies have suggested great potential for the clinical application of stem cell therapy for cardiac disease. Here we will review and summarize the current evidence indicating the potential of stem cell therapy, focusing on the clinical trials conducted to date. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Acute myocardial infarction (AMI) is a leading cause of morbidity, mortality, and disability worldwide [1] . Although advances in mechanical interventions for reperfusion and optimal medical therapies have contributed to a dramatic improvement in clinical outcomes, heart failure after AMI remains a major challenge. Although prompt reperfusion therapy could restore the blood flow of an infarct-related coronary artery and reduce the infarct size, the cardiomyocytes lost during the blockage of blood supply cannot be regenerated. Many patients who survive from myocardial infarction (MI) are often left with a significant impairment of left ventricular systolic function due to ischemic cardiomyopathy triggering the remodeling of the left ventricle and fibrosis. Ischemic cardiomyopathy can lead to a poor quality of life and a poor prognosis with high mortality of more than 25% within the first year of diagnosis [2, 3] . Current treatment strategies, including optimal pharmacotherapy, cardiac resynchronization therapy, and implantable cardioverter-defibrillators, slow progression of the MI to heart failure, improve systolic function, and prevent fatal arrhythmias that can cause sudden cardiac death [4] [5] [6] [7] ; however, they cannot stimulate cell regeneration to recover the loss of functional myocytes. Heart transplantation has evolved as the final treatment option for end-stage heart failure patients who have severe symptoms despite several medical therapies, but this option is available to only a few patients because of the lack of donors and the prohibitively high cost [8] . Hence, there is an unmet need to develop methods to reduce damage to cardiomyocytes and regenerate functional myocardium.
While it was previously believed that the heart has negligible intrinsic regenerative capacity and undergoes limited renewal, over the past decades several experimental studies have shown that cardiomyocytes may be able to undergo mitosis [9, 10] and initiate limited regeneration through the recruitment of residential or circulating stem cells to the damaged site in the heart [11] . Clinical studies have supported the use of stem cells as a potential thera-peutic modality to regenerate damaged myocardium and restore cardiac function (Table 1) [12] . The stem cells that have been transplanted into damaged myocardium show successful engraftment and generate new cardiomyocytes by transdifferentiation or cell fusion [13] ; in addition, the injected stem cells also have paracrine effects [14] . Thus, cell-based therapy using stem cells, which is also known as cellular cardiomyoplasty, has emerged as a strategy to prevent and reverse myocardial injury and to promote myocardial regeneration. Here we review the status of research on cell-based therapy for cardiovascular diseases, focusing on the relevant clinical trials conducted so far.
MECHANISM OF CELL-BASED THERAPY
Stem cells are undifferentiated and primitive cells that can differentiate into multiple cell lineages and have the capacity of renewing themselves through cell division. Precursor or progenitor cells are a type of partially differentiated, usually unipotent, cells that can differentiate into only one cell type, and divide only a limited number of times. These cells have been widely used to regenerate various damaged tissues in animal models [15, 16] . The basic concept of cell-based therapy for cardiovascular diseases is that stem cells extracted from the source are delivered to the damaged tissue, where they grow and differentiate into cardiomyocytes to heal the damaged heart. The mechanism of myocardial regeneration by stem cells is as follows: 1) Cardiomyocyte regeneration resulting from the transdifferentiation of stem cells [17] , 2) Proliferation of endogenous cardiomyocytes by cell fusion with stem cells [18] , 3) Paracrine signaling effects of the stem cells [14] and 4) Reduced cardiomyocyte apoptosis by neovascularization ( Fig. 1) [19] . Human embryonic stem cells (ESCs) are derived from the inner cell mass of the embryo in the blastocyte stage; ESCs are considered the most pluripotent cells and can differentiate into many cell lineages. The potential for using differentiated human embryonic stem cells to treat damaged heart has long been evident bases on the results of preclinical studies [20, 21] . However, no human clinical study has been performed so far because of the ethical issues concerning the use of embryos and the risk of teratoma 
TYPES OF STEM CELLS FOR CELL-BASED THERAPY

Bone marrow derived mononuclear cells
Bone marrow elements have been shown to contribute to cardiac repair in the infarcted heart in animal studies [22] . Orlic et al.
have reported that lineage-negative, c-kit-positive bone marrowderived cells can differentiate into new cardiomyocytes after MI [11] . In 2002, the first clinical trial of intracoronary, autologous BMMNC transplantation for improving cardiac function and myocardial perfusion in patients after acute MI was reported [23] .
After standard therapy for AMI, the BMMNCs aspirated from the ilium of the patients were transplanted during balloon dilatation through a balloon catheter placed into the infarct-related artery. and revascularization were better in the study group than in the placebo group (23% vs 39%, P = 0.01) [25] . The STAR-heart study showed that intracoronary BMC therapy improves ventricular performance, quality of life, and survival not only in the acute phase of MI, but also in chronic ischemic cardiomyopathy [26] . after AMI did not improve LV function at 4 months of follow-up [30] . Recent RCTs including the FOCUS-CCTRN trial [31] , late TIME trial [32] , and TIME trial [33] could not show any benefits of cell therapy. controlled trial with a large study population of up to 3,000 patients. that can be made available as "off the shelf," would be more cost effective and easier to administer and could potentially allow the delivery of greater numbers of cells than autologous cell therapy.
Mesenchymal stem cells
Resident cardiac stem cells
For decades, the human heart was recognized as a terminally differentiated organ; however, several studies have reported that a population of stem cells within the myocardium can differentiate into cardiac myocytes [44] [45] [46] . Despite the unclear origin of CSCs, they can be isolated from the heart tissue and expanded ex vivo for use in cell-based therapy. In the Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO) trial, autologous CSCs were isolated from the right appendage during cardiac surgery and reinfused intracoronarily. No adverse effect was observed and the LVEF increased in the treated patients along with an improvement in the functions and quality of life at 4 months after therapy [47] .
In addition, the Cardiosphere-Derived Autologous Stem Cells to reverse ventricular dysfunction (CADUCEUS) study, in which the stem cells were obtained by percutaneous endomyocardial biopsies, showed that viable heart mass and regional contractility, analyzed by cMRI, increased in the treated patients [48, 49] .
Circulating blood-derived progenitor cells
Circulating blood-derived progenitor cells, which are mainly feasibility, and safety of autologous myoblast transplantation into the infarcted myocardium [54] . However, the early clinical studies of myoblast transplantation in the post-infarct myocardium suggested the possibility of a proarrhythmic effect [55, 56] . Two trials, the MAGIC trial [57] and the SEISMIC trial [58] , showed no significant changes in terms of global and regional LV function in skeletal myoblast-treated patients, and the MARVEL trial was prematurely terminated due to the occurrence of sustained ventricular tachycardia [59] . These multiple negative results and concerns about fatal arrhythmia make it unlikely that myoblast-based cell therapy will be further pursued.
Induced pluripotent stem cells
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